Patent SG-11201903825S-A (SG)
Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
Inventor: VEERAPATHRAN ANAND
IPC: C12N5/0784
Filed: 2017-10-31
Abstract: • 200- • • 6. • w I • •• • Il i* 3 100 - 0 M10151 - HG. 1 W O 20 18/08 17 89 Al M1016T n (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIPO I PCT olimion o III m inono iflo oimIE (10) International Publication Number WO 2018/081789 Al (51) International Patent Classification: C12N 5/0784 (2010.01) C12N 5/0783 (2010.01) C12N 5/078 (2010.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2017/059271 (22) International Filing Date: 31 October 2017 (31.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/415,274 31 October 2016 (31.10.2016) US 62/438,600 23 December 2016 (23.12.2016) US 62/475,053 22 March 2017 (22.03.2017) US 62/481,831 05 April 2017 (05.04.2017) US (71) Applicant: IOVANCE BIOTHERAPEUTICS, INC. [US/US]; 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). (72) Inventors: VEERAPATHARAN, Anand; 15208 Fiji Isle Place, Tampa, FL 33647 (US). GOKULDASS, Aish- warya; 51 Venus Colony, Sithalapakkam, Chennai 600126 (IN). RABINOVICH, Brian; 21 Bellevue Avenue, Win- chester, MA 01890 (US). LOTZE, Michael, T.; 5134 Westminster Place, Pittsburgh, PA 15232 (US). (74) Agent: WALLS, Thomas, H. et al.; Morgan Lewis & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: ENGINEERED ARTIFICIAL ANTIGEN PRESENTING CELLS FOR TUMOR INFILTRATING LYMPHOCYTE EX- = PANSION (57) : In some embodiments, compositions and methods re- lating to isolated artificial antigen presenting cells (aAPCs) are dis- closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A/B/C, ICOS-L, and CD58, and wherein the one or more viral vectors com- prise a nucleic acid encoding CD86 and a nucleic acid encoding 4- 1BBL and/or OX4OL and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX4OL proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed. [Continued on next page] WO 2018/081789 Al MIDEDIMOMMIDIREIDIONIMHOIDEEEHMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))